The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 13, 2010

Filed:

Aug. 25, 2006
Applicants:

Reinhard Bredehorst, Hamburg, DE;

Kerstin Greunke, Hamburg, DE;

Thomas Grunwald, Hamburg, DE;

Edzard Spillner, Hamburg, DE;

Inventors:

Reinhard Bredehorst, Hamburg, DE;

Kerstin Greunke, Hamburg, DE;

Thomas Grunwald, Hamburg, DE;

Edzard Spillner, Hamburg, DE;

Assignee:

PLS-Design GmbH, Hamburg, DE;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); A61K 39/395 (2006.01);
U.S. Cl.
CPC ...
Abstract

This invention relates to the field of recombinant antibody technology. It provides novel recombinant IgY antibody constructs for diagnostic and therapeutical applications. The bivalent antibody constructs display a heterotetrameric or homodimeric format stabilized by disulfide bonds. The constant heavy chain domains C2-C4 are partly or completely of avian origin, whereas the V, V, C, and C1 domains as well as the hinge region may be of avian origin or derived from any other species. The invention allows to combine the advantages of IgY antibodies with those of established mammalian monoclonal antibodies. IgY antibody constructs comprising nonglycosylated IgY constant heavy chain domains allow to reduce unwanted interactions with C-type lectins, e.g., in human sera. Furthermore, chimeric IgY antibody containing mammalian V, V, C, and C1 domains as well as a mammalian hinge region provide a higher molecular stability than IgY antibodies in acidic conditions and, thereby, are especially suited for peroral therapeutic applications.


Find Patent Forward Citations

Loading…